[CRME] Cardiome Pharma Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.99 Change: 0.36 (13.69%)
Ext. hours: Change: 0 (0%)

chart CRME

Refresh chart

Strongest Trends Summary For CRME

CRME is in the long-term down -82% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cardiome Pharma Corp., a biopharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies that enhance the life and health of patients. It offers BRINAVESS (vernakalant IV), for conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company?s pre-clinical research and development focuses on modulating cellular proteins (ion channels) that gate the movement of ions across the cell membrane to control various functions, including contraction of muscles, secretion from glands, and responses to foreign bodies and inflammation. It has operations in Canada, the United States, Switzerland, and the United Kingdom. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities-100 K Cash From Operating Activities-3.17 M Gross Profit4.27 M
Net Profit-3.89 M Operating Profit-2.66 M Total Assets42.65 M Total Current Assets25.09 M
Total Current Liabilities13.96 M Total Debt12 M Total Liabilities28.59 M Total Revenue5.5 M
Technical Data
High 52 week4.71 Low 52 week1.29 Last close2.27 Last change0%
RSI50 Average true range0.1 Beta0.94 Volume128.18 K
Simple moving average 20 days-1.05% Simple moving average 50 days9.09% Simple moving average 200 days12.77%
Performance Data
Performance Week-2.57% Performance Month-3.81% Performance Quart63.31% Performance Half52.35%
Performance Year-31.63% Performance Year-to-date46.45% Volatility daily2.18% Volatility weekly4.88%
Volatility monthly10% Volatility yearly34.63% Relative Volume275.87% Average Volume166.43 K
New High New Low

News

2018-05-17 11:34:00 | Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV

2018-05-17 07:00:00 | Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China

2018-05-15 16:11:26 | Cardiome: 1Q Earnings Snapshot

2018-05-15 16:00:00 | Correvio Reports First Quarter 2018 Financial Results

2018-05-15 08:40:00 | Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals

2018-05-10 07:00:00 | Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call

2018-05-08 09:02:07 | Cardiome Pharma Corp TSE:COM: Should The Recent Earnings Drop Worry You?

2018-04-26 16:33:00 | Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference

2018-04-17 08:00:00 | Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

2018-04-12 07:00:00 | Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018

2018-04-09 14:15:00 | CRME: Cipher to Get Canadian Assets

2018-04-06 18:00:00 | Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds

2018-04-02 08:00:00 | Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission

2018-03-28 08:00:00 | Cardiome Announces Recent Insider Purchases

2018-03-22 08:05:00 | Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts Target Price, Financial Review

2018-03-22 08:00:00 | Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

2018-03-22 07:30:00 | Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash

2018-03-21 16:36:55 | Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares

2018-03-20 07:00:00 | Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

2018-03-19 10:30:00 | CRME: Cardiome’s 2017 Full Year Results

2018-03-13 19:49:33 | Cardiome reports 4Q loss

2018-03-13 16:00:00 | Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results

2018-03-13 12:15:00 | Cardiome Pharma Corp. to Host Earnings Call

2018-03-08 08:07:00 | Marapharm Ventures Inc. Appoints Corey Klassen as Vice President of Corporate Development, Hires CFO and Adds Additional Independent Director

2018-03-06 16:30:00 | Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13

2018-03-06 14:11:09 | Cardiome Pharma Corp TSE:COM: Is Breakeven Near?

2018-02-26 16:11:09 | Are Cardiome Pharma Corp’s TSE:COM Interest Costs Too High?

2018-02-15 11:02:25 | Best TSX Growth Stocks

2018-02-08 08:00:00 | Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference

2018-02-05 11:00:00 | CRME: Initiating Coverage

2018-01-23 08:00:00 | Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

2018-01-10 08:00:00 | Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

2017-12-12 08:00:00 | Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

2017-12-11 12:16:06 | With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp TSX:COM Underperform Its Industry?

2017-12-11 06:00:00 | Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

2017-11-30 09:35:46 | Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017

2017-11-20 08:00:00 | Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

2017-11-16 05:14:39 | Cardiome reports 3Q loss

2017-11-14 16:01:00 | Cardiome Reports Third Quarter 2017 Financial Results

2017-11-14 11:00:00 | Cardiome Pharma Corp. to Host Earnings Call

2017-11-07 08:00:00 | Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

2017-11-07 06:55:13 | What’s Installed For Cardiome Pharma Corp TSX:COM?

2017-11-02 08:00:00 | Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

2017-10-30 08:00:00 | Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies

2017-10-22 18:16:11 | Cardiome Pharma Corp TSX:COM: Time For A Financial Health Check

2017-09-13 11:33:20 | Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017

2017-09-12 07:00:00 | Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® Ceftobiprole in Europe and Israel

2017-09-06 08:30:00 | Cardiome, Pipeline Offers Opportunities Beyond Brinavess

2017-09-05 08:00:00 | Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

2017-08-30 08:00:00 | New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS®